

CURRICULUM VITAE

Prof. dr. TENG Y. K. Onno, MD PhD
Nephrologist
Department Medicine - Nephrology
Leiden University Medical Center (LUMC)

February 23, 2024

PERSONAL INFORMATION

Titles	Professor, MD, PhD
First names	Yoe Kie Onno
Surname	Teng
Birth date	January 28, 1981
Nationality	Dutch
Professional address	Leiden University Medical Center Department of Nephrology (C7-Q) Albinusdreef 2 2333 ZA Leiden The Netherlands T: 00-31-71-5262214 / 99423(pGSM) F: 00-31-71-5266868 E: y.k.o.teng@lumc.nl

Professional web profiles

Publons Account	https://publons.com/researcher/1534334/yoe-kie-onno-teng/
Orcid ID	https://orcid.org/0000-0001-9920-2195
LinkedIn	linkedin.com/in/y-k-onno-teng-6382155


Narrative summary

* Clinical activities: I am a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC). I am the head of the Nephrology outpatient clinic and the national and European recognized center of expertise for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs). I also lead and coordinate a clinical, multidisciplinary pathway aimed at counselling and guiding a pregnancy wish of patients with systemic lupus erythematosus (SLE) or antiphospholipid syndrome.


* Scientific activities: Since the beginning from my academic career, I have organized a clinical research program for the development of novel treatment strategies in patients with a renal autoimmune diseases including lupus nephritis and ANCA associated vasculitis. Simultaneously, I conduct a translational research program focused on neutrophil extracellular traps, B-cell & plasma cell immunology which enables us to perform innovative immunomonitoring in patients with LuVaCs managed with novel treatment strategies.

* Teaching activities: I am actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at the Leiden University. I teach and supervise medical students for their scientific internships as well as clinical internships as part of the Medicine curriculum. Clinical bedside teaching of the LUMC Internal Medicine residents. I have supervised 7 MD-PhD students to date.

Professional Experience and (Inter-)national Responsibilities



Research Activities & Grant support



EXECUTIVE SUMMARY OF CV

Academic Appointments

March 2023- present	Professor in Nephrology focused at Renal Autoimmune diseases
May 2019 - present	Head of Center of Expertise for Lupus- Vasculitis- and Complement-mediated Systemic diseases (LuVaCs)
2021	LuVaCs CoE: National recognition by National Federation of University Medical Centers (NFU)
2022	LuVaCs CoE: International recognition by European Reference Networks ERK-NET and RITA
May 2014 – May 2022	Chief Outpatient Clinic Nephrology
Jan 2014 – present	Nephrologist

Current clinical and research responsibilities

2022 – present	<p>President for the AutoImmune Research & Collaboration Hub (ARCH) Foundation</p> <p><i>National foundation aimed at improving the national care system for patients with rare systemic autoimmune diseases funded by Dutch Arthritis Foundation, supported by the Dutch Society for Rheumatology and the Dutch Society for Nephrology</i></p>
2018 - 2022	<p>Regional and National Lead on several ARCH-projects to improve the national care system for patients with rare systemic autoimmune diseases funded by Dutch Arthritis Foundation:</p> <ul style="list-style-type: none">- on ANCA-associated vasculitis (AAV):<ul style="list-style-type: none">* National consensus on the diagnosis and treatment of AAV in NL* Conducting a national audit on clinical practice variation in AAV care- on regional networks of expertise:<ul style="list-style-type: none">* organizing, structuring, coordinating and collaborating 6 regional networks throughout the Netherlands- on ARCH digital portal for regional, multidisciplinary meetings for patients with rare systemic autoimmune diseases:<ul style="list-style-type: none">* co-creating a digital application for standardised medical data sharing between professionals and hospitals
2014 – present	<p>National and international Principal Investigator for several phase 3, randomized studies on novel treatment strategies for patients with</p> <ul style="list-style-type: none">- Lupus Nephritis:<ul style="list-style-type: none">* Synbiose 1 (rituximab + belimumab), LUMC* Synbiose 2 (belimumab + rituximab), LUMC & Netherlands* BLISS-LN (belimumab), global RCT* BLISS-BELIEVE (belimumab + rituximab), global RCT* AURORA-1 (voclosporin), global RCT* AURORA-2 (voclosporin extended use), global RCT* SIRIUS-LN (ianalumab), global RCT- ANCA-associated vasculitis:<ul style="list-style-type: none">* MoRiA (rituximab), LUMC* ENDURRANCE (rituximab + cyclophosphamide), LUMC & Netherlands* ADVOCATE (avacopan), global RCT* AVAC-EUR (avacopan), European multicentre retrospective study

- Complement-mediated diseases
- * APPEAR-C3G, global RCT

2014 - present	Direct supervisor and co-promotor of 11 MD-PhD students (3 completed)
2014 - present	Expert Consultant to European Commission, ZorgInstituut Nederland (ZiN – Ministry of Health), Alexion Pharmaceuticals, Aurinia Pharmaceuticals, GlaxoSmithKline, KezarBio, Novartis, Otsuka Pharmaceuticals, Vifor Pharma

List of publications

Please click on link for a continuous updated list of publications in Web of Science:

Publons Account <https://publons.com/researcher/1534334/yoe-kie-onno-teng/>

Orcid ID <https://orcid.org/0000-0001-9920-2195>

Citation report Web of Science

<i>Date: 23 February 2024</i>	
Publications	132
Citing Articles	2188 (total)
	2135 (without self-citations)
Times Cited	2936 (total)
	2829 (without self-citations)
Average Citations per Item	22.24
H-index	26

Top-5 Influential publications, including number of citations

<i>Date: 23 February 2024</i>		
No.	Authors, Title, Journal	Citations
1	<i>2019 Update of the Joint European League Against Rheumatism and European Renal Association– European Dialysis and Transplant Association (EULAR/ERA– EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79: 713–723. doi:10.1136/annrheumdis-2020-216924</i> Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO , van Leew B, Bertsias G, Jayne D, Boumpas DT.	413
2	<i>Treatment of Lupus Nephritis with Belimumab: A 2-year randomized controlled trial. New Engl J Med 2020 sept 17; 383 (12): 1117-1128</i> Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO , Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth D.	400
3	<i>Voclosporin efficacy and safety in lupus nephritis (AURORA 1): A phase 3 double-blind, randomised, multi-centre, placebo-controlled trial. Lancet 2021, 397 (10289) , pp.2070-2080</i> Rovin BH, Teng YKO , Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Haplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB.	199

4	<i>The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.</i> <u>J Autoimmun 2018; 91: 45-54</u> Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO .	94
5	<i>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</i> <u>Ann Rheum Dis 2023; DOI 10.1136/ard-2022-223764</u> Hellmich, B; Sanchez-Alamo, B; Schirmer, JH; Berti, A; Blockmans, D; Cid, MC; Holle, JU; Hollinger, N; Karadag, O; Kronbichler, A; Little, MA; Luqmani, RA; Mahr, A; Merkel, PA; Mohammad, AJ; Monti, S; Mukhtyar, CB; Musial, J; Price-Kuehne, F; Segelmark, M; Teng, YKO ; Terrier, B; Tomasson, G; Vaglio, A; Vassilopoulos, D; Verhoeven, P; Jayne, D	76

Top-5 First/Last author Influential publications, including number of citations

Date: 23 February 2024

No.	Authors, Title, Journal	Citations
1	<i>Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.</i> <u>Arthritis Rheumatol 2007; 12: 3909-3918</u> Teng YK , Levarht EWN; Hashemi M, Bajema IM, Toes REM, Huizinga TWJ, van Laar JM.	136
2	<i>The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.</i> <u>J Autoimmun 2018; 91: 45-54</u> Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO .	94
3	<i>Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.</i> <u>BMJ Open 2019 Mar 20; 9 (3): e025687</u> Teng YKO , Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.	72
4	<i>Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA.</i> <u>Kidney Int 2018; 94(1): 139-149</u> Kraaij T, Kamerling SWA, van Dam LS, Bakker JA, Bajema IM, Page T, Brunini F, Pusey CD, Toes REM, Scherer HU, Rabelink TJ, van Kooten C, Teng YKO .	63
5	<i>Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Compared to Systemic Lupus Erythematosus.</i> <u>Arthritis Rheumatol 2019; 71:2 047-2058</u> van Dam LS, Kraaij T, Kamerling SWA, Bakker JA, Scherer UH, Rabelink TJ, van Kooten C, Teng YKO .	51